Claims for Patent: 9,358,301

Summary for Patent: 9,358,301

Title:	Reverse thermal gels and uses therefor
Abstract:	Biodegradable triblock copolymer compositions are provided which are useful in tissue engineering and drug delivery. The copolymers are reverse thermal gels in that when heated from a lower temperature to a higher temperature, they gel. These gels are useful in drug delivery when complexed with an active agent. For example the compositions can be used for intraocular injection of active agents, such as anti-angiogenic agents for treatment of a maculopathy or retinitis.
Inventor(s):	Friberg; Thomas Richard (Pittsburgh, PA), Park; Daewon (Pittsburgh, PA), Wang; Yadong (Bradford Woods, PA)
Assignee:	University of Pittsburgh-Of the Commonwealth System of Higher Education (Pittsburgh, PA)
Application Number:	14/831,142
Patent Claims:	1. A method of treating an ocular disease, disorder, or condition in a patient, comprising delivering to an eye of the patient a reverse thermal gel composition comprising an active agent in an amount effective to treat the ocular disease, disorder, or condition and a triblock copolymer having the structure B-A-B in which A is one of a polyurethane or poly(ester urethane) group that comprises one or more pendant amine groups, blocked amine groups or active agents and B is a hydrophilic block and the composition is a gel at 37.degree. C. and a liquid at a lower temperature, wherein A is a copolymer of a diol and a diisocyanate. 2. The method of claim 1, wherein the active agent is one or more of an antibiotic, an anti-inflammatory agent, an antiangiogenic agent, a hormone, a cytokine, a chemokine, a growth factor, a peptide, and a cell. 3. The method of claim 2, wherein the cell is a stem cell, and wherein the ocular disease, disorder, or condition is age-related macular degeneration. 4. The method of claim 1, wherein the active agent is one or more of: pegaptanib sodium; lucentis; tryptophanyl-tRNA synthetase (TrpRS); AdPEDF; VEGF TRAP-EYE; AG-013958; bevacizumab; ranibizumab; JSM6427; TG100801; ATG3; perceiva; E10030; ARC1905; volociximab; endostatin; vatalanib; pazopanib; sirolimus; bevasiranib; AGN211745; nepafenac; ketorolac tromethamine; acetaminophen; bromfenac; ciprofloxacin; norfloxacin; ofloxacin; levofloxacin; gentamicin; tobramycin; neomycin; erythromycin; trimethoprim sulphate; polymyxin B; ganciclovir and fomivirsen. 5. The method of claim 1, wherein the ocular disease, disorder, or condition is age-related macular degeneration. 6. The method of claim 5, wherein the active agent is bevacizumab. 7. The method of claim 6, wherein the composition is delivered to vitreous humour of at least one eye of the patient. 8. The method of claim 7, wherein the composition is delivered by injection into the vitreous humour. 9. The method of claim 1, wherein the ocular disease, disorder, or condition is diabetic retinopathy. 10. The method of claim 9, wherein the composition is delivered to vitreous humour of at least one eye of the patient. 11. The method of claim 10, wherein the composition is delivered by injection into the vitreous humour. 12. The method of claim 1, wherein the ocular disease, disorder, or condition is glaucoma. 13. The method of claim 12, wherein the composition is delivered to vitreous humour of at least one eye of the patient. 14. The method of claim 13, wherein the composition is delivered by injection into the vitreous humour. 15. A method of treating age-related macular degeneration in a patient, comprising delivering to vitreous humour of at least one eye of the patient a reverse thermal gel composition comprising an anti-angiogenic agent in an amount effective to treat the ocular disease, disorder, or condition and a triblock copolymer having the structure B-A-B in which A is one of a polyurethane or poly(ester urethane) group that comprises one or more pendant amine groups, blocked amine groups or active agents and B is a hydrophilic block and the composition is a gel at 37.degree. C. and a liquid at a lower temperature, wherein A is a copolymer of a diol and a diisocyanate. 16. The method of claim 15, wherein the anti-angiogenic agent is one or more of pegaptanib sodium; tryptophanyl-tRNA synthetase; an adenoviral vector-delivered pigment epithelium-derived factor; aflibercept; a receptor tyrosine kinase inhibitor; bevacizumab; a multi-targeted kinase inhibitor; an ubiquitin-like-conjugating enzyme; rapamycin; a platelet-derived growth factor antagonist; a vascular endothelial growth factor antagonist; ARC190; volociximab; endostatin; ranibizumab; vatalanib; pazopanib; AL-39324; bevasiranib; small interfering RNA; a nicotinic acetylcholine receptor antagonist; and an integrin antagonist. 17. The method of claim 15, wherein the anti-angiogenic agent is bevacizumab. 18. The method of claim 15, wherein the anti-angiogenic agent is ranibizumab. 19. The method of claim 15, wherein the reverse thermal gel composition further comprises at least one stem cell.

Details for Patent 9,358,301

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2030-03-05
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006		2030-03-05
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012		2030-03-05
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016		2030-03-05
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	03/20/2018		2030-03-05